PEPTIDE COMPARISON

AOD-9604 vs Tirzepatide

An unapproved growth-hormone fragment compared with an approved dual-incretin medicine.

QUICK ANSWER

AOD-9604 vs Tirzepatide: the main difference.

Tirzepatide has decision-grade human evidence and product-specific approvals; AOD-9604 does not. The comparison is principally one of clinical maturity, not two equivalent weight-loss options.

Decision field	AOD-9604	Tirzepatide
Human research	Development did not establish persuasive obesity efficacy	Large randomized metabolic programs
Mechanism	Growth-hormone fragment	GIP and GLP-1 receptor agonist
FDA status	Not approved	Approved branded products for defined indications
Clinical maturity	Low	High for labeled uses
Main boundary	Preclinical and mechanistic claims exceed outcomes evidence	Label and formulation remain product-specific

SOURCES

AOD-9604 vs Tirzepatide sources.

FDA / 2024AOD-9604 Pharmacy Compounding Advisory Committee briefingU.S. FDA FDA / 2026Bulk substances that may present significant safety risksU.S. FDA WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2026Zepbound prescribing informationU.S. FDA FDA / 2024FDA approves first medication for obstructive sleep apneaU.S. FDA

AOD-9604 vs Tirzepatide: the main difference.

AOD-9604 vs Tirzepatide sources.

Questions related to AOD-9604 vs Tirzepatide.

Compare the next decision.